Nexplanon (Etonogestrel)

Etonogestrel, the active ingredient in Nexplanon, is a synthetic progestin presented as a subcutaneous implant for subcutaneous administration. It provides long‑acting hormonal contraception by preventing ovulation and altering cervical mucus, intended for use by women of reproductive age seeking reliable birth control.

GNH USA supplies Nexplanon as a licensed, GDP‑compliant international pharmaceutical supplier, delivering the product to hospitals, pharmacies and clinics worldwide with adherence to quality standards and regulatory requirements, including secure packaging and traceability for global distribution through established logistics.

Nexplanon, a progestin hormonal contraceptive, is indicated for prevention of pregnancy.

- Prevention of pregnancy: provides continuous contraception for up to three years. - Management of menstrual irregularities: may reduce frequency of heavy bleeding in some users. - Hormonal regulation: assists in stabilizing hormone levels for contraceptive purposes.

Common Side Effects: - Irregular vaginal bleeding or spotting. - Amenorrhea (absence of periods). - Headache. - Acne or oily skin. - Weight gain. - Breast tenderness.

Serious or Rare Side Effects: - Deep vein thrombosis or pulmonary embolism. - Severe allergic reaction (anaphylaxis). - Infection at the insertion site. - Ectopic pregnancy. - Hormonal hyperplasia. - Persistent severe abdominal pain.

Before insertion, a thorough medical assessment is required to identify contraindications and risk factors.

- Pregnancy: contraindicated; category X – do not use in pregnant women. - Breastfeeding: not recommended during lactation. - Smoking: avoid use in women over 35 who smoke due to increased cardiovascular risk. - Medical history: assess for thromboembolic disorders, liver disease, or hormone‑sensitive cancers. - Drug interactions: review concomitant medications that may reduce contraceptive efficacy. - Store at below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Etonogestrel may interact with several medications that affect its plasma concentration.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin) – may reduce effectiveness. - Rifampin – decreases plasma levels of etonogestrel. - Certain antiretroviral protease inhibitors – may alter hormone metabolism.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole) – may increase hormone levels. - Broad‑spectrum antibiotics (e.g., ampicillin) – minimal effect but monitor for breakthrough bleeding. - Herbal supplements such as St. John's wort – may reduce contraceptive effectiveness.